TNP-470
Star0
Identification
- Generic Name
- TNP-470
- DrugBank Accession Number
- DB08633
- Background
O-(chloroacetylcarbamoyl)fumagillol (TNP-470) has been used in trials studying the treatment of HIV Infections, Sarcoma, Kaposi, and Pancreatic Neoplasms.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 401.882
Monoisotopic: 401.16051534 - Chemical Formula
- C19H28ClNO6
- Synonyms
- O-(chloroacetylcarbamoyl)fumagillol
- O-chloroacetylcarbamoylfumagillol
- External IDs
- AGM 1470
- AGM-1470
- DRG-0148
- NSC-642492
- TNP 470
- TNP-470
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UMethionine aminopeptidase 2 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAlendronic acid The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when TNP-470 is combined with Alendronic acid. Ambroxol The risk or severity of methemoglobinemia can be increased when TNP-470 is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when TNP-470 is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when TNP-470 is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when TNP-470 is combined with Benzyl alcohol. - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as carbamate esters. These are compounds containing an ester of carbamic acid with the general structure R2NC(=O)OR' (R' not H). They are esters of carbamic acids.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Carbamate esters
- Alternative Parents
- Dicarboximides / Organic carbonic acids and derivatives / Oxacyclic compounds / Epoxides / Dialkyl ethers / Organopnictogen compounds / Organonitrogen compounds / Organochlorides / Organic oxides / Hydrocarbon derivatives show 2 more
- Substituents
- Aliphatic heteropolycyclic compound / Alkyl chloride / Alkyl halide / Carbamic acid ester / Carbonic acid derivative / Carbonyl group / Dialkyl ether / Dicarboximide / Ether / Hydrocarbon derivative show 11 more
- Molecular Framework
- Aliphatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- X47GR46481
- CAS number
- 129298-91-5
- InChI Key
- MSHZHSPISPJWHW-PVDLLORBSA-N
- InChI
- InChI=1S/C19H28ClNO6/c1-11(2)5-6-13-18(3,27-13)16-15(24-4)12(7-8-19(16)10-25-19)26-17(23)21-14(22)9-20/h5,12-13,15-16H,6-10H2,1-4H3,(H,21,22,23)/t12-,13-,15-,16-,18+,19+/m1/s1
- IUPAC Name
- (3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl N-(2-chloroacetyl)carbamate
- SMILES
- [H][C@]1(CC=C(C)C)O[C@]1(C)[C@@]1([H])[C@]([H])(OC)[C@@]([H])(CC[C@]11CO1)OC(=O)NC(=O)CCl
References
- General References
- Not Available
- External Links
- PubChem Compound
- 369976
- PubChem Substance
- 99445104
- ChemSpider
- 328427
- BindingDB
- 17446
- ChEBI
- 90748
- ChEMBL
- CHEMBL424278
- ZINC
- ZINC000003914617
- PDBe Ligand
- TN4
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 2 Terminated Treatment Pancreatic Neoplasms 1 1 Completed Treatment Human Immunodeficiency Virus (HIV) Infections / Kaposi's Sarcoma 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0234 mg/mL ALOGPS logP 2.52 ALOGPS logP 2.24 Chemaxon logS -4.2 ALOGPS pKa (Strongest Acidic) 9.71 Chemaxon pKa (Strongest Basic) -3.7 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 89.69 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 98.45 m3·mol-1 Chemaxon Polarizability 41.46 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9886 Blood Brain Barrier + 0.7707 Caco-2 permeable - 0.5611 P-glycoprotein substrate Substrate 0.647 P-glycoprotein inhibitor I Inhibitor 0.7156 P-glycoprotein inhibitor II Inhibitor 0.5513 Renal organic cation transporter Non-inhibitor 0.8603 CYP450 2C9 substrate Non-substrate 0.8027 CYP450 2D6 substrate Non-substrate 0.8334 CYP450 3A4 substrate Substrate 0.7758 CYP450 1A2 substrate Non-inhibitor 0.6951 CYP450 2C9 inhibitor Non-inhibitor 0.7222 CYP450 2D6 inhibitor Non-inhibitor 0.8919 CYP450 2C19 inhibitor Non-inhibitor 0.6379 CYP450 3A4 inhibitor Non-inhibitor 0.5666 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7177 Ames test AMES toxic 0.5347 Carcinogenicity Non-carcinogens 0.828 Biodegradation Not ready biodegradable 0.9852 Rat acute toxicity 2.8117 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9776 hERG inhibition (predictor II) Non-inhibitor 0.8006
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0uxr-2277900000-ec80becff2f2b42429b4 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0089-1095000000-cd7bb16fd6f42550b76d Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0f89-4966400000-8ef54061dd009b49836f Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-0002-1090000000-c90afe1e0a4fc992dfba Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0a5c-8924000000-a9a9f20edbe77ad0215b Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-01ec-7954000000-05701a1b1d079480f79c Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 206.6340444 predictedDarkChem Lite v0.1.0 [M-H]- 197.82173 predictedDeepCCS 1.0 (2019) [M+H]+ 205.7970444 predictedDarkChem Lite v0.1.0 [M+H]+ 199.64664 predictedDeepCCS 1.0 (2019) [M+Na]+ 207.0979444 predictedDarkChem Lite v0.1.0 [M+Na]+ 205.25246 predictedDeepCCS 1.0 (2019)
Targets
![](https://go.drugbank.com/assets/locked/DrugTargets2-682eb846d210ae4bf33ca03febccfb57bb1c61318e699b729e5df4dfab2c5b67.png)
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsMethionine aminopeptidase 2
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Poly(a) rna binding
- Specific Function
- Cotranslationally removes the N-terminal methionine from nascent proteins. The N-terminal methionine is often cleaved when the second residue in the primary sequence is small and uncharged (Met-Ala...
- Gene Name
- METAP2
- Uniprot ID
- P50579
- Uniprot Name
- Methionine aminopeptidase 2
- Molecular Weight
- 52891.145 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Drug created at September 15, 2010 21:33 / Updated at June 12, 2020 16:52